Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors

Biomaterials

Volumn 51, Issue , 2015, Pages 208-215

  Wang, Edina C ^a,b   Min, Yuanzeng ^a,b   Palm, Robert C ^a,b   Fiordalisi, James J ^b   Wagner, Kyle T ^a,b   Hyder, Nabeel ^a,b   Cox, Adrienne D ^b   Caster, Joseph M ^a   Tian, Xi ^a,b   Wang, Andrew Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Controlled drug release; Drug delivery; Nanoparticle

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; NANOPARTICLES; RADIOTHERAPY; TARGETED DRUG DELIVERY; TUMORS;

CANCER RADIOTHERAPIES; CONTROLLED DRUG RELEASE; HISTONE DEACETYLASE INHIBITOR; NANOPARTICLE FORMULATION; PROSTATE CARCINOMA; SECOND GENERATION; THERAPEUTIC POTENTIALS; THERAPEUTIC RATIOS;

CONTROLLED DRUG DELIVERY;

HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; NANOPARTICLE; QUISINOSTAT; VORINOSTAT; H2AFX PROTEIN, HUMAN; HISTONE; HYDROXAMIC ACID; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELLS; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; GENE LOCUS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOFABRICATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION RESPONSE; RADIOSENSITIZATION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; METABOLISM; NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHEMORADIOTHERAPY; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 84924869222     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.015     Document Type: Article

References (23)

1. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
2. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. JClin Oncol 2009, 27:5459-5468.
3. Piekarz R.L., Frye R., Turner M., Wright J.J., Allen S.L., Kirschbaum M.H., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. JClin Oncol 2009, 27:5410-5417.
4. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncol 2007, 12:1247-1252.
5. Halperin E., Perez C., Brady L. Perez and Brady's principles and practice of radiation oncology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. ed.
6. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62:223-229.
7. Flatmark K., Nome R., Folkvord S., Bratland A., Rasmussen H., Ellefsen M., et al. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol 2006, 1:25.
8. Chen C.-S., Wang Y.-C., Yang H.-C., Huang P.-H., Kulp S.K., Yang C.-C., et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007, 67:5318-5327.
9. Munshi A., Tanaka T., Hobbs M.L., Tucker S.L., Richon V.M., Meyn R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol Cancer Ther 2006, 5:1967-1974.
10. Camphausen K., Burgan W., Cerra M., Oswald K.A., Trepel J.B., Lee M.-J., et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64:316-321.
11. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. JBiol Chem 1998, 273:5858-5868.
12. Camphausen K., Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. JClin Oncol 2007, 25:4051-4056.
13. Arts J., King P., Mariën A., Floren W., Beliën A., Janssen L., et al. JNJ-26481585, a novel "Second-Generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res 2009, 15:6841-6851.
14. Lee J.H., Choy M.L., Ngo L., Foster S.S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci 2010, 107:14639-14644.
15. Venugopal B., Baird R., Kristeleit R.S., Plummer R., Cowan R., Stewart A., et al. Aphase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res 2013, 19:4262-4272.
16. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
17. Pridgen E.M., Langer R., Farokhzad O.C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine (Lond) 2007, 2:669-680.
18. Zhang L., Chan J.M., Gu F.X., Rhee J.-W., Wang A.Z., Radovic-Moreno A.F., et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008, 2:1696-1702.
19. Makadia H.K., Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3:1377-1397.
20. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. JControl Release 2000, 65:271-284.
21. Ree A.H., Dueland S., Folkvord S., Hole K.H., Seierstad T., Johansen M., et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the pelvic radiation and vorinostat (PRAVO) phase 1 study. Lancet Oncol 2010, 11:459-464.
22. Kelly W., O'Connor O., Krug L., Chiao J., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. JClin Oncol 2005, 23:3923-3931.
23. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.